Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.

Related Articles

Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.

Mol Cell Endocrinol. 2012 Oct 23;

Authors: Mast N, Linger M, Pikuleva IA

Abstract
In vertebrates, the biosynthesis of steroid hormones is initiated by cytochrome P450 CYP11A1 which converts cholesterol to pregnenolone. We investigated whether some of the experimental and FDA-approved therapeutic agents alter the activity of CYP11A1 in the reconstituted system in vitro. We found that under the experimental conditions used and when phospholipids are included, ketoconazole, posaconazole, carbenoxolone, and selegiline inhibit CYP11A1-mediated production of pregnenolone by at least 67%. Conversely, pemirolast, clobenpropit, desogestrel, dexmedetomidine, and tizanidine stimulate the enzyme activity by up to 70%. We then evaluated the identified inhibitors and activators for spectral binding to CYP11A1 and their effect on enzyme activity in the absence of phospholipids. The data obtained provide insight into how different drugs interact with CYP11A1 and demonstrate that P450 association with the lipid bilayer determines, in many cases, a drug's effect on enzyme activity.

PMID: 23089212 [PubMed - as supplied by publisher]